Downscaled engineered heart tissues of entirely hiPSC-derived 3-cell-type co-culture are functional and viable over several weeks
Laura Windt (Leiden University Medical Center)
M. Wiendels (Leiden University Medical Center)
M. Dostanic (TU Delft - Electronic Components, Technology and Materials, Leiden University Medical Center)
M. Bellin (Leiden University Medical Center)
P. M. Sarro (TU Delft - Electronic Components, Technology and Materials)
M. Mastrangeli (TU Delft - Electronic Components, Technology and Materials)
Christine Mummery (Leiden University Medical Center)
Berend J. van Meer (Leiden University Medical Center)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Microphysiological systems consisting of multiple cell types of the human heart have been shown to recapitulate certain aspects of human physiology better than conventional 2D in vitro models [1]. Engineered heart tissues (EHTs) that self-organise into contractile 3D structures between two flexible pillars are particularly useful to measure contraction against a force. However, conventional EHTs typically require between 50,000 and 2,000,000 cells, which makes creating many EHTs for high throughput screening costly [2]. Here, we show that downscaling EHT size, in our case to include human-induced pluripotent stem cell-derived cardiomyocytes (70%), cardiac fibroblasts (15%) and cardiac endothelial cells (15%), is feasible using as few as 16,000 cells. Tissues of three different sizes formed as expected and consistently, with 47,000, 31,000, and 16,000 cells. Moreover, while keeping the load constant relative to the size of the tissue [3], there was no difference in the viability nor functionality up to 14 days after formation. Electrical pacing of the tissues was conducted within the range of 1 to 3 Hz and with an optimal pacing frequency of 1.4 Hz, which is consistent over the three EHT sizes. Our results indicate that downscaled EHTs might be used as a cost-effective alternative to larger EHTs in drug discovery.